✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Afimoxifene is an investigational drug.
There have been 5 clinical trials for Afimoxifene. The most recent clinical trial was a Phase 2 trial, which was initiated on May 31st 2017.
The most common disease conditions in clinical trials are Carcinoma in Situ, Carcinoma, and Breast Neoplasms. The leading clinical trial sponsors are National Cancer Institute (NCI), Northwestern University, and BHR Pharma, LLC.
Recent Clinical Trials for Afimoxifene
|Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast||National Cancer Institute (NCI)||Phase 2|
|Topical Afimoxifene in Treating Patients With Breast Cancer Who Have Undergone Radiation Therapy on One Breast||Northwestern University||Phase 2|
|Testing an Active Form of Tamoxifen (4-hydroxytamoxifen) Delivered Through the Breast Skin to Control Ductal Carcinoma in Situ (DCIS) of the Breast||BHR Pharma, LLC||Phase 2|